BiomX Past Earnings Performance
Past criteria checks 0/6
BiomX's earnings have been declining at an average annual rate of -8.1%, while the Biotechs industry saw earnings growing at 16.6% annually.
Key information
-8.1%
Earnings growth rate
51.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -162.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How BiomX makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -37 | 10 | 15 |
| 31 Dec 23 | 0 | -26 | 10 | 16 |
| 30 Sep 23 | 0 | -27 | 9 | 16 |
| 30 Jun 23 | 0 | -25 | 10 | 14 |
| 31 Mar 23 | 0 | -27 | 10 | 15 |
| 31 Dec 22 | 0 | -28 | 11 | 15 |
| 30 Sep 22 | 0 | -33 | 11 | 19 |
| 30 Jun 22 | 0 | -36 | 12 | 22 |
| 31 Mar 22 | 0 | -36 | 12 | 21 |
| 31 Dec 21 | 0 | -36 | 12 | 22 |
| 30 Sep 21 | 0 | -35 | 12 | 22 |
| 30 Jun 21 | 0 | -34 | 11 | 21 |
| 31 Mar 21 | 0 | -33 | 10 | 21 |
| 31 Dec 20 | 0 | -30 | 10 | 19 |
| 30 Sep 20 | 0 | -27 | 11 | 18 |
| 30 Jun 20 | 0 | -23 | 11 | 15 |
| 31 Mar 20 | 0 | -22 | 10 | 14 |
| 31 Dec 19 | 0 | -21 | 9 | 13 |
| 30 Sep 19 | 0 | -22 | 5 | 11 |
| 30 Jun 19 | 0 | -19 | 4 | 11 |
| 31 Mar 19 | 0 | -17 | 4 | 10 |
| 31 Dec 18 | 0 | -15 | 3 | 9 |
| 31 Dec 17 | 0 | -7 | 3 | 4 |
Quality Earnings: PHGE is currently unprofitable.
Growing Profit Margin: PHGE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHGE is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.
Accelerating Growth: Unable to compare PHGE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHGE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: PHGE has a negative Return on Equity (-162.33%), as it is currently unprofitable.